Adenosine-d13

• Description:

  Adenosine-d13 (Adenine riboside-d13; D-Adenosine-d13) is deuterium labeled Adenosine (HY-B0228) . Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.

• Product Name Alternative:

  Adenine riboside-d13; D-Adenosine-d13

• UNSPSC:

  12352005

• Target:

  Apoptosis; Autophagy; Endogenous Metabolite; Isotope-Labeled Compounds; Nucleoside Antimetabolite/Analog

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer; Metabolic Disease

• Purity:

  96.6

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]N([2H])C1=NC([2H])=NC2=C1N=C([2H])N2[C@]3([2H])O[C@@](C([2H])([2H])O[2H])([2H])[C@](O[2H])([2H])[C@]3([2H])O[2H]

• Molecular Formula:

  C10D13N5O4

• Molecular Weight:

  280.32

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Zhou XT, et al. Inhibition of autophagy enhances adenosine induced apoptosis in human hepatoblastoma HepG2 cells. Oncol Rep. 2019;41 (2) :829-838.|[3]Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology. 2009;111 (4) :904-915.|[4]Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol Rev. 2018;98 (3) :1591-1625.|[5]Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14 (7) :1315-1323.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported